.jpeg)
2026-06-12 02:50:16
This article provides a comprehensive overview of pegloticase (brand name Krystexxa), a targeted biologic therapy for refractory chronic gout. It covers standard dosage, pre-infusion preparation, infusion procedures, management of infusion reactions, efficacy assessment criteria, special population considerations, and patient follow-up requirements for patients and healthcare professionals.
2026-06-11 05:08:17
This article delves into the mechanism of action of Leflunomide, a synthetic DMARD, detailing its clinical applications in rheumatoid arthritis, psoriatic arthritis, and lupus nephritis, along with comparisons to other therapies.
2026-06-11 02:51:16
This article details the efficacy assessment after the standard 6-month course of Pegloticase, exploring two maintenance strategies (continued infusion vs. switch to oral urate-lowering therapy), the critical role of anti-drug antibody (ADA) monitoring, and long-term safety data for chronic gout management.
2026-06-02 06:09:19
Avacopan is an oral selective complement C5a receptor inhibitor used in combination with immunosuppressants for the treatment of adult anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Proper dose management and safety monitoring are crucial for successful therapy.
2026-04-20 04:06:29
Urece (generic name: dotinurad) is a highly selective urate reabsorption inhibitor developed by Fuji Yakuhin, Japan. It has been approved in Japan, China, and other countries for the treatment of adult patients with gout and hyperuricemia.
2026-02-09 05:42:31
Upatinib (Rift) ®） As an oral JAK inhibitor, it has been approved for various immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, etc. The target population is mainly moderate to severe patients, especially suitable for adults who have insufficient response to traditional treatment, need oral convenience, or have poor injection compliance.
2026-02-06 06:18:41
Biktarvy (Bictegravir, Emtricitabine, Tenofovir Disoproxil Fumarate) is a single-tablet, triple-antiretroviral compound containing Bictegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate, which rapidly blocks viral replication through dual inhibition of integrase and reverse transcriptase. The success rate of reducing viral load to the detection limit within 48 hours is over 80%, and the rate of virological failure after 96 weeks of long-term treatment is less than 1%. It has good safety (mainly mild to moderate adverse reactions), significantly improves CD4+ cell count, and is a preferred first-line treatment for HIV-1 infection. It should be used under the guidance of a doctor and in accordance with prescribed standards.
2026-01-15 05:54:14
Celecoxib is a selective COX-2 inhibitor that exerts anti-inflammatory and analgesic effects to relieve the symptoms of cervical spondylosis (such as radiculopathy type and cervical type).
